Pumitamig plus docetaxel demonstrated encouraging responses in squamous and non-squamous non-small cell lung cancer across PD-L1 expression levels with a confirmed objective response rate of ...
ROSETTA Lung-107 shows pumitamig plus docetaxel achieved 36.7% ORR and 6.9-month PFS after chemoimmunotherapy in metastatic NSCLC.
Pumitamig plus docetaxel demonstrated a confirmed objective response rate of 36.7% in patients with non-small cell lung ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results